Navigation Links
Amgen Completes Acquisition of KAI Pharmaceuticals
Date:7/5/2012

THOUSAND OAKS, Calif., July 5, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco. The acquisition was initially announced April 10, 2012 and includes KAI's lead product candidate KAI-4169, which is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis.  KAI has previously reported compelling Phase 2a clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K.  Amgen is providing this information as of the date of this news release an
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
9. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
10. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
11. CryoLife Completes Acquisition of Hemosphere
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ariz. , July 10, 2014   Ventana ...  Group, today announced it has entered into an agreement ... which operates as EMD Serono in the ... , to collaborate with Merck KGaA,s biopharmaceutical division on ... for an undisclosed target using Ventana,s proprietary diagnostic assays. ...
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  ... to sales of $2,202,000 for the prior year period, an ... also shown growth over the preceding quarter,s sales, continuing a ... year. Markets that experienced sales increases over the prior year ...
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
(Date:7/12/2014)... Passenger Information System market is estimated to grow from ... at an expected CAGR of 26.5% for the period ... in North America is well developed and network infrastructure ... the region. The growing ridership figures in public transport ... driving the North American Passenger Information System market at ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The rise ... has urged for new advanced network architectures to suit ... the IT industry with increasing cloud storage technologies. The ... advent of more mobility devices. This has resulted in ... the main driving forces for the SDN market. , ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... way to guarantee that a surgical technique used to grind ... increase the risk of spreading cancer to other parts of ... advisory panel to the Food and Drug Administration also said ... power morcellation -- should sign a written consent stating that ...
(Date:7/12/2014)... July 12, 2014 In ... report, ‘cognitive assessment and training’ is defined ... assess, train, or enhance cognitive functions. These ... as in dementia screening, clinical trials, driver’s ... learning, self assessment, brain training, and employers’ ...
(Date:7/12/2014)... The Security Analytics market is estimated to grow ... 2019, at an expected CAGR of 9.7% for the ... the increasing number of security breaches, continued line of ... in organizations are enormous. Vendors in the security analytics ... to develop better and more secure systems. , There ...
Breaking Medicine News(10 mins):Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... , Post-hoc analysis of two large clinical trials showed ... HDL, triglycerides and LDL than the pre-determined therapy alone ... (NYSE: ABT ) TRILIPIX (R) (fenofibric acid) ... and combined lipid targets in patients with mixed dyslipidemia ...
... Appoints Longtime Cardinal Health Executive to Advance Strategic Growth ... 8 Sarnova, the nation,s leading specialty distributor of health ... markets, announced today that it has appointed Hank Struik ... Cardinal Health, Inc., Mr. Struik, 42, brings more than ...
... Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the ... offer to acquire outstanding common stock purchase warrants. The ... the transactions described below will not be registered under the ... offered or sold in the United States absent registration or ...
... director of the CyberKnife Center of Miami ( http://www.cyberknifemiami.com ... by the South Florida Business Journal. , , According to Dr. ... as successful Miami businessmen who are among the upper echelon of leaders ... include the following people: , , , ...
... focus on family-building benefits for its employees , , ... CVS ) is proud to announce it has been named ... the country for offering superior family-building benefits, such as health ... adoptions, and paid and unpaid leave for birth and adoptions. ...
... On June 7th, Little Hearts, Inc. held their 13th ... the support services they offer is their "Picture of Hope" ... in age from infant to 50 of all different types ... TGA, TOF and Tricuspid Atresia. "HOPE" is shared with others ...
Cached Medicine News:Health News:Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets 2Health News:Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets 3Health News:Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets 4Health News:Sarnova Names Hank Struik Chief Executive Officer 2Health News:Sarnova Names Hank Struik Chief Executive Officer 3Health News:Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants 2Health News:Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants 3Health News:CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America 2Health News:CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America 3Health News:Members of National CHD Organization Unite for Little Hearts' Celebration and Assemble for 'Picture of Hope' 2
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... The new Synchron LXi 725 ... technology with highly accurate immunoassay testing ... sample handling on a single platform. ... are automatically repeated for optimal quality ...
...
...
Medicine Products: